Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US

Khawaja M. Talha, MBBS; Javed Butler, MD, MPH, MBA; Stephen J. Greene, MD; Rahul Aggarwal, MD; Stefan D. Anker, MD, PhD; Brian L. Claggett, PhD; Scott D. Solomon, MD; John J. V. McMurray, MD; Muthiah Vaduganathan, MD, MPH; Gregg C. Fonarow, MD

IMPORTANCE The expansion of sodium-glucose cotransporter-2 (SGLT-2) inhibitor use in patients with heart failure (HF) and left ventricular ejection fraction (LVEF) more than 40% following the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) and the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trials have major implications in the US.

OBJECTIVE To quantify the estimated US population-level impact of reducing worsening HF events with SGLT-2 inhibitors in individuals with LVEF more than 40%.

DESIGN, SETTING, AND PARTICIPANTS This decision analytical model study used self-reported HF data from the National Health and Nutritional Examination Survey from 2015 to 2018, which was weighted across the entire US population and subsequently mapped onto newly eligible LVEF distributions from the Get With The Guidelines–Heart Failure registry. All patients older than 18 years with HF from the National Health and Nutritional Examination Survey were grouped into the following categories: all LVEF and LVEF more than 40%. Numbers needed to treat estimations over 3 years were obtained for outcome measures from the EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction), EMPEROR-Preserved, DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), and DELIVER trials.

MAIN OUTCOMES AND MEASURES Worsening HF events (unplanned HF hospitalizations, urgent HF visits requiring intravenous therapy, or cardiovascular death).

RESULTS A projected 4,794,524 (95% CI, 3,997,363-5,591,684) adults (57% male; 67% White; mean age, 66 years) with HF would be eligible for SGLT-2 inhibitors. Of this total population, 2,619,248 (95% CI, 2,183,759-3,054,737) would be estimated as newly eligible with LVEF more than 40%. Based on estimates from the EMPEROR-Reduced/EMPEROR-Preserved and DAPA-HF/DELIVER trials, a projected 624,247 (95% CI, 520,457-728,037) to 627,124 (95% CI, 522,855-731,392) worsening HF events could be prevented across the LVEF spectrum with SGLT-2 inhibitors over 3 years, of which 232,589 (95% CI, 193,918-271,260) to 282,879 (95% CI, 235,846-329,912) events could be prevented in individuals with LVEF more than 40%. Moreover, an estimated 468,904 (95% CI, 390,942-546,867) to 499,110 (95% CI, 416,125-582,094) total HF hospitalizations could be prevented across the LVEF spectrum, of which 172,870 (95% CI, 144,128-201,613) to 231,018 (95% CI, 192,608-269,428) could be prevented in individuals with LVEF more than 40%.

CONCLUSIONS AND RELEVANCE In addition to the proven benefit in HF with LVEF of 40% and less, optimal implementation of SGLT-2 inhibitor therapy for HF with LVEF more than 40% can potentially prevent/postpone an additional approximately 250,000 worsening HF events over 3 years in the US.
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors were initially designed to decrease heart failure (HF) hospitalizations and cardiovascular (CV) deaths in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial that was specifically designed to assess efficacy and safety of empagliflozin in patients with type 2 diabetes. Subsequently, in DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction), SGLT-2 inhibitors were found to reduce CV death and HF hospitalizations in patients with HF with reduced ejection fraction, irrespective of diabetes status. More recently, the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) trial reported a significant reduction in the composite outcome of CV death or HF hospitalization with empagliflozin in patients with HF and a left ventricular ejection fraction (LVEF) more than 40%, ie, with mildly reduced or preserved ejection fraction. Similar findings were reported in the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial, which reported a significant reduction in the composite outcome of HF hospitalizations, urgent HF visits, or CV deaths.

We sought to estimate the potential US population-level implications of SGLT-2 inhibitor therapy in HF by performing a decision analytical model study of all participants in the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, and DELIVER trials. We also aim to assess the benefit of the expansion of SGLT-2 inhibitors therapy to patients with HF with LVEF more than 40% by the US Food and Drug Administration in the rates of worsening HF events, CV deaths, and adverse drug events.

Methods

National Health and Nutritional Examination Survey

The National Health and Nutritional Examination Survey (NHANES), which is a biannually conducted survey designed to project national prevalence estimates of diseases in the US, was used to estimate the weighted prevalence of patients with HF in the US. Estimates of self-reported HF from 2015 to 2018 (n = 19,255) were obtained, as performed by Vaduganathan et al. The following criteria were applied to the initial cohort to determine a clinically actionable population of interest: patients 18 years and older with a diagnosis of HF irrespective of LVEF were included, and patients with an estimated glomerular filtration rate (<20 mL/min/1.73 m²) and systolic blood pressure less than 100 mm Hg were excluded. Blood pressure measurements were obtained by physical examination and estimated glomerular filtration rate was determined based on creatinine measurements. In a sensitivity analysis, the following exclusions were further applied: patients undergoing inotropic support or hospice/comfort care, ventricular assist device or heart transplant recipients, type 1 diabetes, and patients with New York Heart Association functional class 1 symptoms.

Findings

In this decision analytical model study of 4,794,524 adults with HF in the US, a total of 2,619,248 patients with LVEF more than 40% were newly eligible for SGLT-2 inhibitor therapy. With the optimal implementation of SGLT-2 inhibitors over 3 years, an estimated 630,000 worsening HF events were projected to be prevented/postponed across the LVEF spectrum, of which approximately 230,000 to 280,000 would be prevented/postponed in HF with LVEF more than 40%.

Get With The Guidelines–Heart Failure Registry

Data were obtained from the American Heart Association Get With The Guidelines–Heart Failure (GWTG-HF) registry to identify a distribution of LVEF among patients 18 years and older hospitalized between January 1, 2014, and September 30, 2019, at 529 US hospitals. Population-level estimates were ascertained for the following groups: (1) all patients with HF irrespective of LVEF in the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, and DELIVER trials and (2) HF with LVEF more than 40%, including all patients in the EMPEROR-Preserved and DELIVER trials.

End Point Assessment

The EMPEROR trials primarily assessed the composite end point of CV death or HF hospitalization. The DAPA-HF and DELIVER trials primarily assessed the composite end point of worsening HF event (including unplanned HF hospitalizations or urgent visits requiring intravenous therapy) or CV death. Both trials also studied the occurrence of total (first and recurrent) HF hospitalizations, which were included in this analysis. We designated the following end points for assessment of population-level impact, standardized over 1 and 3 years: (1) total (first and recurrent) HF hospitalizations, (2) composite of total (first and recurrent) HF hospitalizations and CV deaths, and (3) composite of worsening HF event (expanded composite inclusive of urgent HF visits and total HF hospitalizations) or CV death. Urgent HF visits were urgent or emergency visits for HF that required intravenous therapy.

Adverse Events

The following adverse events of interest were also assessed and standardized at 1 and 3 years: (1) symptomatic hypotension (investigator-defined events, no blood pressure cutoff as mentioned in the EMPEROR-Preserved trial) and (2) genital infections. To avoid heterogeneity in reporting projected population

Key Points

**Question** What is the population-level impact in the US of comprehensive implementation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) more than 40%?

**Findings** In this decision analytical model study of 4,794,524 adults with HF in the US, a total of 2,619,248 patients with LVEF more than 40% were newly eligible for SGLT-2 inhibitor therapy. With the optimal implementation of SGLT-2 inhibitors over 3 years, an estimated 630,000 worsening HF events were projected to be prevented/postponed across the LVEF spectrum, of which approximately 230,000 to 280,000 would be prevented/postponed in HF with LVEF more than 40%.

**Get With The Guidelines–Heart Failure Registry** Data were obtained from the American Heart Association Get With The Guidelines–Heart Failure (GWTG-HF) registry to identify a distribution of LVEF among patients 18 years and older hospitalized between January 1, 2014, and September 30, 2019, at 529 US hospitals. Population-level estimates were ascertained for the following groups: (1) all patients with HF irrespective of LVEF in the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, and DELIVER trials and (2) HF with LVEF more than 40%, including all patients in the EMPEROR-Preserved and DELIVER trials.

**End Point Assessment** The EMPEROR trials primarily assessed the composite end point of CV death or HF hospitalization. The DAPA-HF and DELIVER trials primarily assessed the composite end point of worsening HF event (including unplanned HF hospitalizations or urgent visits requiring intravenous therapy) or CV death. Both trials also studied the occurrence of total (first and recurrent) HF hospitalizations, which were included in this analysis. We designated the following end points for assessment of population-level impact, standardized over 1 and 3 years: (1) total (first and recurrent) HF hospitalizations, (2) composite of total (first and recurrent) HF hospitalizations and CV deaths, and (3) composite of worsening HF event (expanded composite inclusive of urgent HF visits and total HF hospitalizations) or CV death. Urgent HF visits were urgent or emergency visits for HF that required intravenous therapy.
The prevalence of self-reported HF among US adults was estimated to be 5,604,076 (95% CI, 4,674,944-6,532,080). After excluding those with systolic blood pressure of less than 100 mm Hg or estimated glomerular filtration rate less than 20 mL/min/1.73 m², 4,794,524 (95% CI, 3,997,363-5,591,684) patients with HF were identified (Figure 1). The mean age was 66.4 (95% CI, 64.8-68.0) years. The total HF population was predominantly male (56.5%) and non-Hispanic White (67.3%). The HF population also included Asian (2.3%), Black (16.1%), other Hispanic (6.4%), Mexican American (4.1%), and individuals of other race and ethnicity (3.8%). Other demographic and clinical characteristics of individuals with HF in NHANES are described in the eTable 2 in the Supplement.

Among 586,580 patients hospitalized for HF in the GWTG-HF registry, 27,060 (4.6%) did not have available data for LVEF. Among those with available data (n = 559,520), relative proportions of patients based on LVEF subgroups, 40% or less and more than 40%, are illustrated in Figure 2. Overall, 45.3% of patients with HF with LVEF 40% or less, an estimated glomerular filtration rate; EMPORER-Preserved, Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction; LVEF, left ventricular ejection fraction.
an additional 2,619,248 (95% CI, 2,183,759-3,054,737) individuals who are eligible to receive SGLT-2 inhibitors.

**Population-Level Treatment Effect Sizes Irrespective of Left Ventricular Ejection Fraction**

Among 9,718 trial participants in the EMPEROR-Reduced and EMPEROR-Preserved trials, the 3-year NNT for total HF hospitalizations, the composite of HF hospitalizations and CV deaths, and worsening HF event or CV death were 10, 9, and 8, respectively (Table 1). The findings were similar among 8,007 participants in the DAPA-HF and DELIVER trials where the 3-year NNT for total HF hospitalizations, the composite of HF hospitalizations and CV deaths, and worsening HF event or CV death were 11, 9, and 8, respectively (Table 1). Based on these estimates, optimal implementation of SGLT-2 inhibitors across the LVEF spectrum is projected to prevent/postpone 499,110 (95% CI, 416,125-582,094) to 468,904 (95% CI, 390,942-546,867) total HF hospitalizations, 562,397 (95% CI, 468,890-655,905) to 591,163 (95% CI, 492,875-689,455) total HF hospitalizations and CV deaths, and 624,247 (95% CI, 520,457-728,039) to 627,124 (95% CI, 522,855-731,392) worsening HF events or CV deaths over a 3-year period (Table 2 and Figure 3).

The 3-year NNH for symptomatic hypotension and genital infections was 70 and 42, respectively. Optimal implementation of SGLT-2 inhibitor therapy could cause a projected 77,672 (95% CI, 64,758-90,585) episodes of symptomatic hypotension and 119,384 (95% CI, 99,535-139,233) patients to experience a genital infection over a 3-year period (Table 2).

**Sensitivity Analysis of Conservative Estimate of Potentially Eligible Treatment Candidates**

In a sensitivity analysis, those with New York Heart Association class I functional status (239,726 [5%]), those receiving hospice care or comfort measures only (191,781 [4%]), inotropic agents, ventricular assist devices, urgent transplant (47,945 [1%]), and those with type 1 diabetes (960 [0.02%]) were additionally excluded. The potential number of adults projected to be eligible ranged from 431,412 (95% CI, 3,956,827-5,031,397) for all LVEFs to 23,567,798 (95% CI, 196,496-2,748,652) for individuals with LVEF more than 40%. Optimal implementation of SGLT-2 inhibitors in this more selected HF population would be expected to avert up to 561,697 (95% CI, 468,306-655,088) to 564,285 (95% CI, 470,465-658,107) worsening HF events or CV deaths across all LVEFs and 209,284 (95% CI, 174,487-244,080) to 254,534 (95% CI, 212,214-296,854) worsening HF events or CV deaths for HF with LVEF more than 40%. Optimal implementation of SGLT-2 inhibitors would be expected to cause up to 107,422 (all LVEF) and 57,978 (LVEF >40%) patients to experience a genital infection. Moreover, it will also be expected to cause 69,889 (all LVEF) and 49,769 (LVEF >40%) patients to experience a symptomatic hypotension event over 3 years.
Table 1. Treatment Effect Sizes and Number Needed to Treat With SGLT-2 Inhibitors in the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, and DELIVER Trials

<table>
<thead>
<tr>
<th>End point</th>
<th>Overall rate (per 100 patient-years)</th>
<th>Overall rate measure (95% CI)</th>
<th>Rate difference, 1-y outcome</th>
<th>Event rate (per 100 patient-years) in the first 3 y</th>
<th>Rate difference, 3-y outcome</th>
<th>Number needed to treat 1-y Outcome</th>
<th>Number needed to treat 3-y Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMPEROR-Reduced and EMPEROR-Preserved trials, all LVEFs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total HF hospitalizations</td>
<td>12.49</td>
<td>9.07</td>
<td>0.72 (0.63-0.83)</td>
<td>5.13</td>
<td>12.56</td>
<td>9.09</td>
<td>10.41</td>
</tr>
<tr>
<td>Total HF hospitalizations and CV deaths</td>
<td>17.58</td>
<td>13.70</td>
<td>0.77 (0.69-0.87)</td>
<td>5.41</td>
<td>17.64</td>
<td>13.73</td>
<td>11.73</td>
</tr>
<tr>
<td>Worsening HF event* or CV death</td>
<td>19.17</td>
<td>14.84</td>
<td>0.76 (0.68-0.86)</td>
<td>6.22</td>
<td>19.22</td>
<td>14.88</td>
<td>13.02</td>
</tr>
<tr>
<td><strong>DAPA-HF and DELIVER trials, all LVEFs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total HF hospitalizations</td>
<td>11.44</td>
<td>8.20</td>
<td>0.72 (0.63-0.82)</td>
<td>4.78</td>
<td>11.47</td>
<td>8.21</td>
<td>9.78</td>
</tr>
<tr>
<td>Total HF hospitalizations and CV deaths</td>
<td>17.34</td>
<td>13.28</td>
<td>0.76 (0.69-0.85)</td>
<td>5.50</td>
<td>17.40</td>
<td>13.29</td>
<td>12.33</td>
</tr>
<tr>
<td>Worsening HF event or CV death</td>
<td>17.78</td>
<td>13.46</td>
<td>0.76 (0.68-0.84)</td>
<td>6.15</td>
<td>17.83</td>
<td>13.47</td>
<td>13.08</td>
</tr>
<tr>
<td><strong>EMPEROR-Preserved trial, LVEF &gt;40%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total HF hospitalizations</td>
<td>8.60</td>
<td>6.46</td>
<td>0.73 (0.60-0.89)</td>
<td>3.74</td>
<td>8.64</td>
<td>6.44</td>
<td>6.60</td>
</tr>
<tr>
<td>Total HF hospitalizations and CV deaths</td>
<td>12.47</td>
<td>9.93</td>
<td>0.78 (0.66-0.93)</td>
<td>3.75</td>
<td>12.48</td>
<td>9.90</td>
<td>7.74</td>
</tr>
<tr>
<td>Worsening HF event or CV death</td>
<td>13.79</td>
<td>10.83</td>
<td>0.77 (0.65-0.91)</td>
<td>4.14</td>
<td>13.78</td>
<td>10.82</td>
<td>8.88</td>
</tr>
<tr>
<td><strong>DELIVER trial, LVEF &gt;40%</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total HF hospitalizations</td>
<td>10.25</td>
<td>7.35</td>
<td>0.72 (0.60-0.85)</td>
<td>5.31</td>
<td>10.30</td>
<td>7.36</td>
<td>8.82</td>
</tr>
<tr>
<td>Total HF hospitalizations and CV deaths</td>
<td>14.04</td>
<td>10.69</td>
<td>0.76 (0.66-0.88)</td>
<td>5.50</td>
<td>14.11</td>
<td>10.73</td>
<td>10.14</td>
</tr>
<tr>
<td>Worsening HF event or CV death</td>
<td>15.33</td>
<td>11.79</td>
<td>0.77 (0.67-0.89)</td>
<td>6.40</td>
<td>15.39</td>
<td>11.79</td>
<td>10.80</td>
</tr>
</tbody>
</table>

Abbreviations: CV, cardiovascular; DAPA-HF, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; DELIVER, Dapagliflozin Evaluation To Improve The Lives Of Patients With Preserved Ejection Fraction Heart Failure; EMPEROR-Preserved, Empagliflozin Outcome Trial In Patients With Chronic Heart Failure With Preserved Ejection Fraction; EMPEROR-Reduced, Empagliflozin Outcome Trial In Patients With Chronic Heart Failure With Reduced Ejection Fraction; HF, heart failure; LVEF, left ventricular ejection fraction; SGLT2, sodium-glucose cotransporter-2.

*Worsening HF events include HF hospitalizations and urgent visits for HF requiring intravenous therapy.
Table 2. Estimated Events Prevented/Postponed or Associated With SGLT-2 Inhibitor Therapy Among Newly Eligible Patients Treated for 3 Years

<table>
<thead>
<tr>
<th>No. (95% CI)</th>
<th>Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total HF hospitalizations and CV deaths</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Estimated events prevented/postponed by the implementation of SGLT-2 inhibitors among newly eligible patients for 3 years</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Worsening HF event or CV death</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Worsening HF events include HF hospitalizations and urgent visits for HF requiring intravenous therapy.</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Abbreviations:
- **CV:** cardiovascular
- **DAPA-HF:** Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
- **DELIVER:** Dapagliflozin Evaluation To Improve The Lives Of Patients With Preserved Ejection Fraction Heart Failure
- **HF:** heart failure
- **LVEF:** left ventricular ejection fraction
- **NA:** not applicable
- **SGLT-2:** sodium-glucose cotransporter-2
- **SGLT-2 inhibitors:** Diabetic nephropathy in patients with Chronic kidney disease with Heart failure and worsening HF, or chronic kidney disease

**Discussion**

The indication for SGLT-2 inhibitors has expanded to patients with HF across the complete LVEF spectrum after the EMPEROR-Preserved trial found a significant reduction in HF events with SGLT-2 inhibitors in HF with LVEF more than 40%. The DELIVER study further confirmed these findings and extended similar benefits in patients regardless of LVEF in those enrolled in the hospital or recently hospitalized and in those with HF with improved LVEF (those with prior LVEF ≤40%).

The current study evaluated the projected benefit of the maximal implementation of both SGLT-2 inhibitors based on the current body of evidence and guideline recommendations. An estimation of approximately 630,000 total worsening HF events or CV deaths are projected to be prevented/postponed over 3 years of SGLT-2 inhibitor therapy across the LVEF spectrum. This includes an estimated prevention/postponement of approximately 230,000 to 280,000 worsening HF events or CV deaths in HF with LVEF more than 40%.

The NNTs for 3 years of treatment for all efficacy end points were similar across the LVEF spectrum included in this study and ranged from 9 to 13 for the composite end point of total HF hospitalizations and CV deaths to 10 to 16 for total HF hospitalizations. The NNTs for LVEF more than 40% were numerically higher overall compared with those for all LVEFs for all efficacy end points. Worsening HF events included urgent HF visits and total (first and recurrent) hospitalizations and were included within an expanded composite end point of worsening HF event or CV death. This was deemed an important outcome for this study as urgent HF visits also represent an indicator of HF morbidity, quality of life, and a measure of HF-associated health care costs. According to a retrospective evaluation of linked US claims data and electronic health records from 2012 to 2018, an estimated 16% of patients with HF with preserved ejection fraction underwent HF hospitalization, while the rate of urgent outpatient HF visits was similar (approximately 12%). More alarmingly, 27% of patients with an urgent outpatient HF visit were admitted to the hospital for HF within 30 days. This contributes to a mean monthly direct health care cost to be approximately $9000 (slightly lower for HF with preserved ejection fraction, approximately $7400).

The projected decrease in HF-associated morbidity that could be achieved with optimal implementation of SGLT-2 inhibitors could substantially reduce the economic burden of HF events on the US health care system. According to a contemporary systematic review of all HF hospitalizations in the US from 2014 to 2020, the mean cost of an HF hospitalization in the US is approximately $13,000 to $14,000. Based on these estimates and total HF hospitalizations projected to be prevented/postponed in this study, maximal implementation of SGLT-2 inhibitors would be expected to reduce the costs of HF hospitalizations by close to $7 billion across the LVEF spectrum and $3 billion in all individuals with HF with LVEF more than 40%. These estimates are optimistic in that they do not account for the cost of SGLT-2 inhibitors given the obvious difficulty in ensuring maximal indicated use of SGLT-2 inhibitors in HF; however, even a more conservative implementa-
A potential barrier to the use of SGLT-2 inhibitors across populations is the perceived notion of adverse reactions associated with the drug among patients and clinicians alike. In this analysis, we included 2 adverse events reported in the EMPOROR trials that were slightly more prevalent in the SGLT-2 inhibitor group: symptomatic hypotension and genital infections. The NNH for both was high across all LVEF subgroups (52 to 70 for symptomatic hypotension and 39 to 42 for genital infections), leading to a maximum of projected 77,672 patients to experience a symptomatic hypotension event and projected 119,384 patients to experience a genital infection across 3 years. The rate difference for genital infections was higher with SGLT-2 inhibitors vs placebo compared with that for symptomatic hypotension; however, uncomplicated infections are not an absolute contraindication to SGLT-2 inhibitors and the risk of complicated genital infections is quite low at less than 3% in the EMPOROR-Preserved trial.

This analysis addresses the optimal implementation of SGLT-2 inhibitors across the US, which is limited by several factors, including the high retail cost of SGLT-2 inhibitors, estimated to be approximately $500 per month. An analysis from the Medical Expenditure Panel Survey\(^1\) from 2014 to 2018 revealed that out-of-pocket costs for SGLT-2 inhibitors were about $140 per month for uninsured patients, while those who were insured by Medicare were still required to pay about $50 per month out of pocket in medication costs. Moreover, most of these patients are older with multiple chronic conditions and are already taking multiple medications, and the addition of this relatively expensive medication, even among insured patients, can be a major deterrent to populationwide SGLT-2 inhibitor uptake. A recent analysis by Vaduganathan et al.\(^2\) suggested that cardiologists comprise only 5% of total prescribing physicians for SGLT-2 inhibitors, with the majority citing insufficient knowledge about the medication and perception of SGLT-2 inhibitors as drugs for diabetes as reasons for not prescribing them. Moreover, another contemporary analysis reported the uptake of SGLT-2 inhibitors in patients with type 2 diabetes and CV disease in less than 2% of the eligible population.\(^3\) Several patient and clinician-related barriers exist to optimal implementation of SGLT-2 inhibitors, which if alleviated can lead to a profound reduction in HF events as discussed in this study.

**Limitations**

The results of this study are subject to certain limitations. First, the projected estimates assume that patients will comply with therapy for 3 years, not accounting for adherence patterns, medication costs, and potential perceived or true adverse reactions causing drug discontinuation. Second, the projected HF population from the NHANES registry is a weighted mean of self-reported HF data in the US and hence may not be a true estimate of HF prevalence. Third, the LVEF distribution obtained from the GWTG-HF registry might not be a true assessment of LVEF distribution across the US population as the GWTG-HF registry derives its data only from patients hospitalized for HF rather than the overall HF population. However, as discussed in a previous similar study by Vaduganathan et al.,\(^4\) the LVEF measured during hospitalizations is usually the most recent, objective assessment of ventricular function, and hence provides a reliable estimate of LVEF distribution in the overall HF population. Fourth, there was heterogeneity in safety end point definition in DAPA-HF and DELIVER trials as data were only collected for serious adverse events or adverse events that led to treatment discontinuation, and hence safety event rates from these 2 trials were not included. Lastly, urgent HF visits may have led to subsequent HF hospitalization and were counted as 2 separate events in the EMPOROR-Reduced and...
EMPEROR-Preserved trials. This may have led to double counting of worsening HF events and overestimation of the treatment effect.

Conclusions

SGLT-2 inhibitors have been expanded to a further 2.6 million patients with HF in the US with mildly reduced and preserved LVEF based on findings from the EMPEROR-Preserved and DELIVER trials. In addition to clinical events prevented among patients with LVEF 40% or lower, optimal implementation is estimated to maximally prevent/postpone a further approximately 250 000 worsening HF events or CV deaths in LVEF more than 40% leading to projected prevention/postponement of approximately 630 000 events across the LVEF spectrum over 3 years, with a low adverse event rate. To mirror this effect in routine clinical practice, efforts are needed to advocate for initiating SGLT-2 inhibitors in HF among hospital systems, clinicians, and patients alike given the magnitude of the morbidity benefits and potential reduction in HF-related health care costs.

ARTICLE INFORMATION

Accepted for Publication: October 10, 2022.
Published Online: November 5, 2022. doi:10.1001/jamacardio.2022.4348

Author Affiliations: Department of Medicine, University of Mississippi Medical Center, Jackson (Talha, Butler); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas (Butler); Division of Cardiology, Duke University School of Medicine, Durham, North Carolina (Greene); Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts (Aggarwal); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Aggarwal, Claggett, Solomon, Vaduganathan); Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany (Anker); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland (McMurray); Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles (Fonarow); Associate Editor, JAMA Cardiology (Fonarow).

Author Contributions: Drs Butler and Fonarow had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Talha, Butler, Fonarow. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Talha, Butler, Fonarow. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Talha, Aggarwal, Claggett. Obtained funding: Solomon. Administrative, technical, or material support: Fonarow. Supervision: Butler, Solomon, Fonarow.

Conflict of Interest Disclosures: Dr Butler reported personal fees from Abbott, Adrenomed, American Regent, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Cardior, CVRx, Eli Lilly and Company, G3 Pharma, Imbria, Impulse Dynamics, Innolife, Janssen, LivaNova, Medtronic, Merck, Novartis, Novo Nordisk, Occlutech, Pfizer, Relypsa, Roche, Sanofi, Sequana Medical, and Vifor for consulting outside the submitted work. Dr Greene reported personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Cortera Therapeutics, Cytokinetics, Merck & Co, PharmAllin, Tricog Health, Sanofi, Urovant Pharmaceuticals; nonfinancial support from AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Sanofi, Pfizer; research support from the Duke University Department of Medicine Chair’s Research Award; American Heart Association; National Heart, Lung, and Blood Institute, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck & Co, Novartis, Pfizer, and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics, and Sanofi; receives research support from Boehringer Ingelheim; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck & Co, PharmAllin, Roche Diagnostics, Sanofi, Urovant Pharmaceuticals, and Vifor outside the submitted work. Dr Anker reported grants from Abbott Vascular and Vifor International and personal fees from Abbott Vascular, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bioventrix, Brahms, Cardiac Dimensions, Cardor, Cordia, CVRx, Edwards, Impulse Dynamics, Janssen, Novartis, Occlutech, Respicardia, Servier, Thermo Fisher Scientific, Vectorious, Vifor, and V-Wave outside the submitted work. Dr Claggett reported personal fees from Amgen, Cardor, Corvia, Novartis, Alynlysin, and Intellia for consulting and from Boehringer Ingelheim outside the submitted work. Dr Solomon reported grants from AstraZeneca paid to their institution during the conduct of the study; grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Boston, Bristol Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Eli Lilly, Med称号; MoxyKardia, National Heart, Lung, and Blood Institute, Neurotronik, Novartis, Novo Nordisk, Respicardia, Sanofi Pasteur, TheraCos, US2.AI paid to their institution; and personal fees from Abbott, Action, Akros, Alynlysin, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardor, Cardorun, Corvia, Cytokinetics, Daiichi Sankyo, GlaxoSmithKline, Eli Lilly, Merck, Myokardia, Novartis, Roche, TheraCos, Quantum, Regeneron, Sanofi, Janssen, Cardiac Dimensions, Tenaya, Sanofi Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Puretech Health for consulting outside the submitted work. Dr Claggett reported personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Corteria Therapeutics, Cytokinetics, Merck & Co, PharmAllin, Tricog Health, Sanofi, Urovant outside the submitted work. Dr Vaduganathan reported personal fees from Amgen, AstraZeneca, American Regent, Baxter HealthCare, Bayer AG, Boehringer Ingelheim, Cytokinetics, Relypsa, Novartis, Roche Diagnostics, Lexicon Pharmaceuticals, Galmed, Medtronic, Impulse Dynamics, and Triogic Health; grant support or served on advisory boards for Pharmacosmos and Sanofi; and participate in clinical trial committees for studies sponsored by Galmed outside the submitted work. Dr Fonarow reported personal fees from Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Eli Lilly, Janssen, Medtronic, Merck, and Novartis outside the submitted work. No other disclosures were reported.

Disclaimer: Dr Fonarow is Associate Editor of JAMA Cardiology but was not involved in any of the decisions regarding review of the manuscript or its acceptance.

Meeting Presentation: This paper was presented at the AHA 2022 Scientific Sessions, November 5, 2022, Chicago, Illinois.

REFERENCES


